Fujifilm Corporation
Scientist
on
September 17, 2025
This installment of Supplier Spotlight® highlights FUJIFILM Corporation, a global contract research organization (CRO) providing drug discovery and preclinical services for cyclic peptide discovery, biological assays utilizing hiPSC-derived cells and discovery platforms for infectious diseases. Their services are available on Scientist.com.
What is your company’s mission?
The Fujifilm Group offers end-to-end support for drug discovery research. Guided by our “Partners for Life” principle, Fujifilm commits to being a true partner to pharmaceutical companies and patients, contributing to the advancement of the pharmaceutical industry.
What products and services do you offer?
The Fujifilm Group leverages its advanced biotechnological and AI technologies expertise, cultivated through a diverse range of business fields, to provide drug discovery support CRO services to pharmaceutical companies and biotech ventures. These services span the discovery of new drug candidates and the evaluation of their efficacy and safety. Our offerings include evaluation services utilizing products from FUJIFILM Cellular Dynamics, Inc., a global leader in iPS cell technology, as well as FUJIFILM’s proprietary human iPS cell-derived intestinal epithelial cells. We also offer high-throughput cyclic peptide discovery services using mRNA display technology, as well as drug discovery platforms in the area of infectious diseases established through more than forty years of research experience with antibiotics.
How will you contribute as Partners for Life?
We support our customers to accelerate drug discovery research for innovative therapeutics as contract research organization by utilizing cutting-edge technologies such as masterful use of iPSC-derived cells, proprietary cyclic peptide discovery methodology, AI-based analysis/prediction and so on. FUJIFILM group also has a CDMO business, and we can provide end-to-end services.
What are the most innovative tools and technologies that you offer?
- Diverse and High-Affinity Cyclic Peptide Discovery Service utilizing mRNA display technology
- Bespoke Neuropharmacology Discovery Services utilizing Human iPSC-Derived Cells with Co/Tri-culture and Cellular Aging Technologies, combined with Advanced Gene Network Analysis
- In vitro electrophysiological assays utilizing iPSC-derived cardiomyocyte and neurons with MEA
- In vitro ADME test utilizing iPSC-derived small intestinal epithelial cells or BBB kit
- Highly specialized bioassessment service for infectious diseases utilizing pathogenic microorganisms
- drug2drugs AI-AAM®, a scaffold hopping service combining structure generation AI with AAM descriptors (Amino-Acid Mapping) that simulate interactions between compounds and proteins
What are your competitive advantages and unique features of your services?
The competitive advantages of our services are built on our extensive drug discovery expertise and cutting-edge technology platforms. Additionally, with our combined capabilities across FUJIFILM group, we can seamlessly support customers throughout the entire process from drug discovery to manufacturing with our global group companies.
The unique features for our services are as follows:
Peptide Discovery Service
- Large-scale library of peptides (≥1013 variants) with non-natural amino acids using mRNA display technology
- High-throughput identification of hit peptides through affinity assays with target protein
- One-stop service from peptide discovery to peptide synthesis and evaluation
hiPSC-Derived Cell-Based Assay Services and Gene Network Analysis
- Bespoke neuropharmacology research services using hiPSCs for CNS drug discovery, including co-culture and 3D tri-culture of neurons, astrocytes and microglia
- Gene Network Analysis for deciphering complex biological interactions, elucidation of drug mechanisms and identification of key gene targets
- Evaluation platforms for cardiotoxicity, neurotoxicity, BBB permeability and more
Infectious Diseases
- Bespoke drug discovery services for anti-infective drugs, covering target identification to IND submission, backed by decades of pharmaceutical experience at FUJIFILM Toyama Chemical Co. Ltd
- Proven experiences in diverse drug discovery modalities, including small molecules, natural products, peptides, antibody-drug conjugates and vaccines for serious, life-threatening infectious diseases
Who are your clients?
Pharma, biotech and academia organizations that are actively developing therapeutics or healthcare/life science products.
Where are your laboratories and offices located?
Our operations are headquartered in Tokyo, Japan. Our locations in Japan are Kanagawa, Toyama and Fukushima. In the EU, we have global CRO business development support functions located in Neuss, Germany.